Drug Profile

BLU 945

Alternative Names: BLU-945; ZL-2313

Latest Information Update: 09 Sep 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Blueprint Medicines
Developer Blueprint Medicines; ZAI Lab
Class Antineoplastics; Small molecules
Mechanism of Action ErbB receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

Highest Development Phases

Discontinued Non-small cell lung cancer

Most Recent Events

06 Mar 2026 Pharmacokinetics data from a phase-I/II trial in Non-small cell lung cancer presented at the 127^th Annual Meeting of the American Society for Clinical Pharmacology and Therapeutics (ASCPT-2026)
18 Jul 2025 Blueprint Medicines has been acquired by Sanofi
07 Jun 2024 Discontinued - Phase-I for Non-small cell lung cancer in China (PO) (Blueprint Medicines Pipeline, June 2024)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com